These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 24722449)
1. Cytomegalovirus and anemia: not just for transplant anymore. Seifert ME; Brennan DC J Am Soc Nephrol; 2014 Aug; 25(8):1613-5. PubMed ID: 24722449 [No Abstract] [Full Text] [Related]
2. Human cytomegalovirus inhibits erythropoietin production. Butler LM; Dzabic M; Bakker F; Davoudi B; Jeffery H; Religa P; Bojakowski K; Yaiw KC; Rahbar A; Söderberg-Naucler C J Am Soc Nephrol; 2014 Aug; 25(8):1669-78. PubMed ID: 24722450 [TBL] [Abstract][Full Text] [Related]
3. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers. Shinfuku A; Shimazaki T; Fujiwara M; Sato F; Watase H; Numazaki T; Kawakita Y; Mutoh M; Yamasaki H; Takayama N; Kato S; Sugimoto T; Maruyama J Am J Nephrol; 2018; 48(3):157-164. PubMed ID: 30176654 [TBL] [Abstract][Full Text] [Related]
4. Home Therapy to Reduce Office Visits for Patients with Chronic Kidney Disease and Anemia. Riley MV; Vess J; Dumas BP Nephrol Nurs J; 2017; 44(1):29-33. PubMed ID: 29237106 [TBL] [Abstract][Full Text] [Related]
5. Collagen Hydrolysate Corrects Anemia in Chronic Kidney Disease via Anti-Inflammatory Renoprotection and HIF-2α-Dependent Erythropoietin and Hepcidin Regulation. Zhu S; Wu L; Zhang J; Miao Y; Zhao Y; Zeng M; Li D; Wu H J Agric Food Chem; 2020 Oct; 68(42):11726-11734. PubMed ID: 32981311 [TBL] [Abstract][Full Text] [Related]
6. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia. Landau D; London L; Bandach I; Segev Y PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538 [TBL] [Abstract][Full Text] [Related]
7. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Kular D; Macdougall IC Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190 [TBL] [Abstract][Full Text] [Related]
8. The Influence of Inflammation on Anemia in CKD Patients. Gluba-Brzózka A; Franczyk B; Olszewski R; Rysz J Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979104 [TBL] [Abstract][Full Text] [Related]
9. How the Target Hemoglobin of Renal Anemia Should Be. Mimura I; Tanaka T; Nangaku M Nephron; 2015; 131(3):202-9. PubMed ID: 26381503 [TBL] [Abstract][Full Text] [Related]
10. Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. Kim IY; Kim JH; Kim MJ; Lee DW; Hwang CG; Han M; Rhee H; Song SH; Seong EY; Lee SB Int Urol Nephrol; 2018 Dec; 50(12):2255-2260. PubMed ID: 30136086 [TBL] [Abstract][Full Text] [Related]
11. Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response. Anusornvongchai T; Nangaku M; Jao TM; Wu CH; Ishimoto Y; Maekawa H; Tanaka T; Shimizu A; Yamamoto M; Suzuki N; Sassa R; Inagi R Kidney Int; 2018 Sep; 94(3):536-550. PubMed ID: 29887316 [TBL] [Abstract][Full Text] [Related]
12. Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia. Yokoro M; Nakayama Y; Yamagishi SI; Ando R; Sugiyama M; Ito S; Yano J; Taguchi K; Kaida Y; Saigusa D; Kimoto M; Abe T; Ueda S; Fukami K J Am Soc Nephrol; 2017 Sep; 28(9):2670-2680. PubMed ID: 28600471 [TBL] [Abstract][Full Text] [Related]
13. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Hanudel MR; Eisenga MF; Rappaport M; Chua K; Qiao B; Jung G; Gabayan V; Gales B; Ramos G; de Jong MA; van Zanden JJ; de Borst MH; Bakker SJL; Nemeth E; Salusky IB; Gaillard CAJM; Ganz T Nephrol Dial Transplant; 2019 Dec; 34(12):2057-2065. PubMed ID: 30007314 [TBL] [Abstract][Full Text] [Related]
14. Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents. Kaufman JS Am J Kidney Dis; 2013 Feb; 61(2):191-3. PubMed ID: 23318011 [No Abstract] [Full Text] [Related]
15. Hepcidin in chronic kidney disease anemia. Santos-Silva A; Ribeiro S; Reis F; Belo L Vitam Horm; 2019; 110():243-264. PubMed ID: 30798815 [TBL] [Abstract][Full Text] [Related]
16. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Lee SW; Kim JM; Lim HJ; Hwang YH; Kim SW; Chung W; Oh KH; Ahn C; Lee KB; Sung SA Sci Rep; 2017 Jun; 7(1):4260. PubMed ID: 28652624 [TBL] [Abstract][Full Text] [Related]
17. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator. Yoshida T; Hayashi M Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of anemia in CKD. Babitt JL; Lin HY J Am Soc Nephrol; 2012 Oct; 23(10):1631-4. PubMed ID: 22935483 [TBL] [Abstract][Full Text] [Related]
19. Management of Anemia and other Hematologic Derangements in Patients with Chronic Kidney Disease. Ansari I; Sheikh A; Ahmed SS; Jabbar Q; Ali S Arab J Nephrol Transplant; 2014 Jan; 7(1):13-9. PubMed ID: 24702529 [TBL] [Abstract][Full Text] [Related]
20. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection]. Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]